147 related articles for article (PubMed ID: 31092420)
1. Differential Prognostic Relevance of Promoter DNA Methylation of
Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
[TBL] [Abstract][Full Text] [Related]
4. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
[TBL] [Abstract][Full Text] [Related]
5. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
6. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
[TBL] [Abstract][Full Text] [Related]
8. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
[TBL] [Abstract][Full Text] [Related]
9. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
Kikuchi M; Katoh H; Waraya M; Tanaka Y; Ishii S; Tanaka T; Nishizawa N; Yokoi K; Minatani N; Ema A; Kosaka Y; Tanino H; Yamashita K; Watanabe M
Cancer Lett; 2017 Jan; 384():70-78. PubMed ID: 27756570
[TBL] [Abstract][Full Text] [Related]
11. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
Harada H; Soeno T; Yokoi K; Nishizawa N; Ushiku H; Hosoda K; Hiki N; Yamashita K
J Surg Res; 2020 Dec; 256():404-412. PubMed ID: 32777557
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
Kojima K; Yamashita K; Ushiku H; Katoh H; Ishii S; Tanaka T; Yokoi K; Suzuki M; Ooizumi Y; Igarashi K; Hosoda K; Moriya H; Mieno H; Katada N; Tanabe S; Watanabe M
Dis Esophagus; 2017 Mar; 30(3):1-9. PubMed ID: 28184414
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
Yokoi K; Harada H; Yokota K; Ishii S; Tanaka T; Nishizawa N; Shimazu M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 Feb; 26(2):406-414. PubMed ID: 30311169
[TBL] [Abstract][Full Text] [Related]
15. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
[TBL] [Abstract][Full Text] [Related]
16. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers.
Brait M; Ling S; Nagpal JK; Chang X; Park HL; Lee J; Okamura J; Yamashita K; Sidransky D; Kim MS
PLoS One; 2012; 7(9):e44951. PubMed ID: 23028699
[TBL] [Abstract][Full Text] [Related]
17. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines.
Jeschke J; O'Hagan HM; Zhang W; Vatapalli R; Calmon MF; Danilova L; Nelkenbrecher C; Van Neste L; Bijsmans IT; Van Engeland M; Gabrielson E; Schuebel KE; Winterpacht A; Baylin SB; Herman JG; Ahuja N
Clin Cancer Res; 2013 Jun; 19(12):3201-11. PubMed ID: 23630167
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer.
Kojima K; Nakamura T; Ooizumi Y; Igarashi K; Tanaka T; Yokoi K; Ishii S; Nishizawa N; Katoh H; Kosaka Y; Sato T; Watanabe M; Yamashita K
PLoS One; 2019; 14(1):e0211108. PubMed ID: 30677088
[TBL] [Abstract][Full Text] [Related]
19. Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer.
Ooki A; Yamashita K; Kikuchi S; Sakuramoto S; Katada N; Kokubo K; Kobayashi H; Kim MS; Sidransky D; Watanabe M
Oncogene; 2010 Jun; 29(22):3263-75. PubMed ID: 20228841
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.
Katoh H; Yamashita K; Waraya M; Margalit O; Ooki A; Tamaki H; Sakagami H; Kokubo K; Sidransky D; Watanabe M
Neoplasia; 2012 Jul; 14(7):559-71. PubMed ID: 22904674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
